Each film-coated tablet contains Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg/100 mg + Dapagliflozin Propanediol Monohydrate equivalent to Dapagliflozin 5 mg/10 mg.

Sitanorm D Tablets combine Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with Dapagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, providing complementary mechanisms to improve glycaemic control in adults with type 2 diabetes mellitus. Sitagliptin enhances glucose-dependent insulin secretion and suppresses glucagon release, while dapagliflozin lowers blood glucose by increasing urinary glucose excretion. This dual-action therapy helps improve glycaemic control with a low intrinsic risk of hypoglycaemia when used appropriately.

Sitanorm D Tablets are indicated for the treatment of adults with type 2 diabetes mellitus inadequately controlled on metformin monotherapy, as an adjunct to diet and exercise to improve glycaemic control.

Dapagliflozin is an SGLT2 inhibitor that reduces renal glucose reabsorption, lowers the renal threshold for glucose, and increases urinary glucose excretion, thereby reducing blood glucose levels. Sitagliptin is a DPP-4 inhibitor that prolongs the activity of incretin hormones by preventing their degradation. This results in increased glucose-dependent insulin secretion and decreased glucagon secretion, improving both fasting and postprandial glycaemic control.

The recommended dosage is one tablet orally once daily, with or without food, or as directed by the physician.

Sitanorm D Tablets are contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis or angioedema, to dapagliflozin, sitagliptin, or any component of the formulation.